Promising but I think still a long way behind NEU. It'll be...

Promising but I think still a long way behind NEU. It'll be interesting to see how effective PYC's drug will be compared with NEU's NNZ2591. I understand they have 2 different ways of correcting the deficiency of the Shank3 protein. Which one will turn out to be more effective? NEU has already successfully completed Stage II trials in the US to test for safety and efficacy in affected children, but PYC still has to embark on Stage I trials to test for safety in healthy humans don't they? NEU could be starting Stage III registrational trials for 2591 in PMS next year. I hold shares in both companies, so there's no cross promotion here.